Table 1.
Patient and study characteristics
| Study characteristics | ADVANCEa | INSIST16 | eNOVAa | BSCORE17 | EXCELLENT18 | Total |
|---|---|---|---|---|---|---|
| Year initiated | 2005 | 2006 | 2006 | 2008 | 2008 | |
| Number of patients | 1899 | 703 | 275 | 3389 | 3459 | 9725 |
| Number of physicians | 602 | 308 | 284 | 354 | 698 | 2246 |
|
| ||||||
| Patient characteristics | Weighted average | |||||
| Mean age, years (±SD) | 63.3 ± 2.3 | 63.9 ± 11.4 | 62.1 ± 12.0 | 63.8 ± 11.9 | 63.8 ± 11.7 | 63.7 ± 11.9 |
| Male sex, % | 50.9 | 49.4 | 51.7 | 53.8 | 54.8 | 53.2 |
| Ethnicity: white, % | 98.9 | 98.0 | 99.5 | n/a | — | — |
| Diabetes mellitus, % | 1.9 | 30.0 | 9.3 | 23.7 | 26.9 | 22.0 |
| Angina, % | 14.6 | 10.9 | 11.6 | — | — | — |
| Myocardial infarction, % | 7.4 | 8.2 | 7.1 | 8.3 | 8.8 | 8.6 |
| Congestive heart failure, % | 4.0 | 2.3 | 3.5 | — | 4.1 | — |
| Current smoker, % | 21.6 | 17.5 | 20.6 | — | — | — |
| Renal impairment, % | 3.7 | 1.2 | 1.7 | — | — | — |
| Metabolic syndrome, % | 25.9 | 26.8 | 24.8 | — | — | — |
|
| ||||||
| Valsartan formulations | ||||||
| 80 mg | ✓ | ✓ | ✓ | |||
| 160 mg | ✓ | ✓ | ✓ | |||
| 80 mg/12.5 mg HCTZ | ✓ | ✓ | ✓ | |||
| 160 mg/12.5 mg HCTZ | ✓ | ✓ | ✓ | |||
| 160 mg/25 mg HCTZ | ✓ | ✓ | ✓ | |||
| 80 mg/5 mg amlodipine | ✓ | |||||
| 160 mg/5 mg amlodipine | ✓ | |||||
| 160 mg/10 mg amlodipine | ✓ | |||||
HCTZ = hydrochlorothiazide.
a
Novartis data on file (unpublished).